TW200410677A - Method of treating osteoarthritis - Google Patents

Method of treating osteoarthritis Download PDF

Info

Publication number
TW200410677A
TW200410677A TW092123032A TW92123032A TW200410677A TW 200410677 A TW200410677 A TW 200410677A TW 092123032 A TW092123032 A TW 092123032A TW 92123032 A TW92123032 A TW 92123032A TW 200410677 A TW200410677 A TW 200410677A
Authority
TW
Taiwan
Prior art keywords
substituted
pain
methyl
dimethyl
hexyloxy
Prior art date
Application number
TW092123032A
Other languages
English (en)
Chinese (zh)
Inventor
Joseph Anthony Cornicelli
Kenneth Stanley Kilgore
Drago Robert Sliskovic
Susan Elizabeth Bove
David Herbert Neideffer
Mark Charles Kowala
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of TW200410677A publication Critical patent/TW200410677A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW092123032A 2002-08-22 2003-08-21 Method of treating osteoarthritis TW200410677A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40525002P 2002-08-22 2002-08-22

Publications (1)

Publication Number Publication Date
TW200410677A true TW200410677A (en) 2004-07-01

Family

ID=31946834

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092123032A TW200410677A (en) 2002-08-22 2003-08-21 Method of treating osteoarthritis

Country Status (13)

Country Link
EP (1) EP1539127A1 (ja)
JP (1) JP2006501238A (ja)
KR (1) KR20050058454A (ja)
CN (1) CN1678297A (ja)
AU (1) AU2003255937A1 (ja)
BR (1) BR0313883A (ja)
CA (1) CA2494544A1 (ja)
IL (1) IL166600A0 (ja)
MX (1) MXPA05001254A (ja)
PL (1) PL375742A1 (ja)
TW (1) TW200410677A (ja)
WO (1) WO2004017952A1 (ja)
ZA (1) ZA200501133B (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI382841B (zh) * 2010-10-29 2013-01-21 Univ China Medical 用於抑制發炎之醫藥組合物

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004105801A1 (en) * 2003-05-30 2004-12-09 Warner-Lambert Company Llc Animal model for the alleviation of pain using il-6
WO2005002557A1 (en) * 2003-07-03 2005-01-13 Warner-Lambert Company Llc Pharmaceutical compositions including an ether and selective cox-2 inhibitor and uses thereof
US20050026979A1 (en) * 2003-07-31 2005-02-03 Maha Ghazzi Methods for treating inflammation and inflammation-associated diseases with a statin and ether
DE102008000237A1 (de) 2007-02-06 2008-08-07 Basf Se Phenol-Imidazolderivate zur Stabilisierung von polymerisationsfähigen Verbindungen
IL181577A0 (en) * 2007-02-26 2007-07-04 Jacob Bar Tana Combination therapy composition and methods for the treatment of cardiovascular disorders and immune-related disorders
US8530420B2 (en) * 2008-12-16 2013-09-10 Kaohsiung Medical University Treatment of arthritis with parathyroid hormone
TW201902471A (zh) * 2017-04-18 2019-01-16 美商珍費爾醫療公司 賈卡賓尼（ｇｅｍｃａｂｅｎｅ）、其醫藥上可接受之鹽、彼等之組成物及使用彼等之方法
EP3867222A4 (en) * 2018-10-18 2022-07-06 Gemphire Therapeutics Inc. GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF, AND METHODS OF USE THEREOF
CN114847223B (zh) * 2022-02-19 2023-11-07 昆明理工大学 一种建立oa食蟹猴模型的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
CN1395555A (zh) * 2000-01-25 2003-02-05 沃尼尔·朗伯公司 二羧酸醚钙、其制备方法、和用其治疗血管疾病和糖尿病的方法
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI382841B (zh) * 2010-10-29 2013-01-21 Univ China Medical 用於抑制發炎之醫藥組合物
US8691796B2 (en) 2010-10-29 2014-04-08 China Medical University Pharmaceutical composition and method for inhibiting inflammation

Also Published As

Publication number Publication date
EP1539127A1 (en) 2005-06-15
CN1678297A (zh) 2005-10-05
IL166600A0 (en) 2006-01-15
BR0313883A (pt) 2005-07-19
CA2494544A1 (en) 2004-03-04
KR20050058454A (ko) 2005-06-16
WO2004017952A1 (en) 2004-03-04
MXPA05001254A (es) 2005-06-08
AU2003255937A1 (en) 2004-03-11
PL375742A1 (en) 2005-12-12
ZA200501133B (en) 2008-01-30
JP2006501238A (ja) 2006-01-12

Similar Documents

Publication Publication Date Title
ZA200501133B (en) Method of treating osteoarthritis
TWI791507B (zh) 使用ccr3-抑制劑治療老化相關損傷之方法及組合物
US20070203212A1 (en) Method of treating osteoarthritis
JP2021073258A (ja) トラジピタントによる治療方法
US20100160351A1 (en) Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
TW200404531A (en) Synergistic combinations
EP2311446A1 (en) Compositions comprising Tramadol and Celecoxib in the treatment of pain
BR112020016500A2 (pt) Agente preventivo ou terapêutico e composição farmacêutica para doença inflamatória ou doença óssea
RU2286151C2 (ru) Комбинации альфа-2-дельта-лиганда с селективным ингибитором циклооксигеназы-2
AU775591B2 (en) Anxiety method
JP2007500690A (ja) スタチンおよびエーテルを用いた炎症および炎症関連疾患の治療方法
RU2760324C1 (ru) Новое применение полоксамера в качестве фармакологически активного вещества
JP2022504184A (ja) ブドウ膜黒色腫の治療のための併用療法
ES2726401T3 (es) Uso de inhibidores de HDAC para el tratamiento de la destrucción ósea
JP2022066434A (ja) ロキソプロフェン又はその塩及びビタミンｅを含有する経口用医薬組成物
TW200303748A (en) Method of treating osteoarthritis
KR20200055117A (ko) Pi3 키나아제 억제제 및 세포독성 항암제를 포함하는 암의 예방 또는 치료용 약학적 조성물
JP7366108B2 (ja) ロキソプロフェン又はその塩及びビタミンｂ１２類を含有する経口用医薬組成物
JP2013522201A (ja) 便秘のためのアリールビニルアザシクロアルカン化合物
JP2006502991A (ja) マトリックスメタロプロテイナーゼ−１３のアロステリックアルキン阻害剤とセレコキシブまたはバルデコキシブではないシクロオキシゲナーゼ−２の選択的阻害剤との組合せ物
JP4522261B2 (ja) ブドウ膜黒色腫の処置
US20050004196A1 (en) Pharmaceutical compositions including an ether and selective COX-2 inhibitor and methods for using such
EA041892B1 (ru) Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторов